Cell and Gene Therapy Strategic Roundup | Jul 29 – Aug 31, 2026
Cell and Gene Therapy Strategic Roundup exploring Developments and Competitive…
Insulinova Partners with Ospedale San Raffaele | Lucid Diligence Brief
Avaí Bio and Insulinova Test Encapsulated Beta Cells With San Raffaele as…
Cell and Gene Therapy Strategic Roundup | June 24–July 29, 2026
Cell and Gene Therapy Strategic Roundup exploring Developments and Competitive…
Endocrinology Strategic Roundup | June 23–July 20, 2026
Strategic Developments and Competitive Shifts in Endocrinology Coverage Period:…
United Therapeutics’ Thymmune acquisition | Lucid Diligence Brief
United Therapeutics adds Thymmune’s iPSC thymic-cell platform to its…
Merck KGaA Bio-Techne Deal | Lucid Diligence Brief
Merck KGaA’s US$11.3bn Bio-Techne acquisition tests workflow depth, integration…
Secretome STM-01 Duchenne Cardiomyopathy | Lucid Diligence Brief
Secretome’s STM-01 faces Duchenne cardiomyopathy endpoint, CMC, and regulatory…
In Vivo CAR-T: Stress-Testing the Lilly–Kelonia Deal with AI-Powered Wargaming
Why the Lilly–Kelonia Deal Matters for In Vivo CAR-T Download the…
Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash
Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash…
Cell and Gene Therapy Today—March 5, 2026
This is a weekly update in gene and cell therapy, covering key regulatory…
Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel)
Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel) Professional…
Cell and Gene Therapy Today—February 19, 2026
This week's update in gene and cell therapy covers notable developments…